Pull to refresh
Logo
Daily Brief
Following
Why Ranks Sign Up
New study finds apoB blood test beats standard LDL screening

New study finds apoB blood test beats standard LDL screening

New Capabilities

A Northwestern model of 250,000 adults shows counting cholesterol particles, not measuring their contents, prevents more heart attacks at a cost payers can absorb

Yesterday: Findings reach a wide audience

Overview

Most Americans who get their cholesterol checked receive an LDL test. A Northwestern Medicine study says a different, rarely ordered test would catch more of the people about to have a heart attack.

The test is apolipoprotein B, or apoB. It counts the actual number of harmful cholesterol particles in your blood, rather than measuring the cholesterol packed inside them. In a model of 250,000 U.S. adults, guiding treatment by apoB prevented more heart attacks and strokes than the standard LDL approach, and did so at a price researchers call good value for health payers.

Why it matters

Heart disease kills more Americans than anything else. A cheap test many patients have never heard of could flag more of the people most likely to die from it.

Questions about this story

No questions yet — be the first to ask.

Key Indicators

250,000
Adults in the model
Simulated U.S. adults eligible for statins with no existing heart disease.
#1
Cause of U.S. deaths
Cardiovascular disease is the leading cause of death in the United States.
1 extra draw
Why apoB is skipped
ApoB is not on standard panels, so ordering it usually means a separate test.
1st
Study of its kind
First comprehensive analysis to show apoB-guided treatment is cost-effective.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Play

Exploring all sides of a story is often best achieved with Play.

Log in to play. Track your picks, climb the leaderboards. Log in Sign Up
Predict 3 ways this could play out. Contrarian picks score more — points lock when the scenario resolves. Log in to play
Higher or Lower Two numbers from this story. Guess which is bigger. 5 rounds to set a streak. Log in to play
Connections Sixteen names from the news. Find the four hidden groups of four. Log in to play

People Involved

Organizations Involved

Timeline

August 2019 July 2026

3 events Latest: Yesterday
  1. Findings reach a wide audience

    Latest Publicity

    News coverage brings the study to general readers, framing apoB as a test millions of patients are not getting.

  2. JAMA publishes the Northwestern study

    Research

    Northwestern researchers report that apoB-guided treatment prevents more heart attacks and strokes than LDL targets, at a cost payers can absorb.

  3. European guidelines flag apoB

    Guideline

    European cardiology and atherosclerosis societies name apoB a useful marker for cardiovascular risk, especially for certain patients.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

November 2008

Statins move to primary prevention (2008)

The JUPITER trial showed rosuvastatin cut heart attacks and strokes in people with normal LDL but high C-reactive protein. It challenged the idea that LDL alone decides who needs treatment. The result reached about 18,000 participants.

Then

Guidelines and prescribing widened to include patients LDL testing had passed over.

Now

Risk-based treatment, not a single cholesterol number, became the model for prevention.

Why this matters now

Like JUPITER, the apoB study argues the standard number misses people who are actually at risk.

2009-2010

HbA1c replaces fasting glucose for diabetes (2009-2010)

An international expert panel recommended the HbA1c blood test to diagnose diabetes. It measured long-term blood sugar and did not require fasting. Major bodies adopted it soon after.

Then

Clinicians gained a more convenient, more stable test for identifying patients.

Now

HbA1c became a routine standard, showing how a better metric can displace an entrenched one.

Why this matters now

Shows the path apoB advocates hope to follow: a better measure becoming the default, if convenience and cost line up.

Sources

(5)